In this article, we look at 10 Small Cap Stocks with Potential to Rise 1000 Percent.
Small-cap stocks have returned to the market’s risk conversation in 2026. The Russell 2000 was up 18.6% year-to-date through June 12, ahead of the Nasdaq, S&P 500, and Dow Jones Industrial Average, while MarketWatch reported that the index was trading near a record high in mid-June. The move has come even as the asset class remains exposed to higher borrowing costs. Reuters noted in May that smaller companies are especially vulnerable to yield spikes because many are still unprofitable and depend more heavily on future cash flows.
That risk profile is also why the upside cases can look extreme. Small-cap stocks are defined as those with market values between $300 million and $2 billion, and within that band, the most aggressive analyst targets are concentrated in biotechnology. The setup is not accidental. EY’s 2026 Biotech Beyond Borders report said biotech financing rose 11% to $68.5 billion in 2025, while Reuters reported that first-quarter 2026 biotech M&A reached $84 billion, nearly double the prior-year level. For speculative small-cap drug developers, clinical data, regulatory progress, partnerships, or takeover interest can sharply reset valuations, which is why some names still carry several hundred percent implied upside.
Methodology
For this article, we screened small-cap stocks with market capitalizations between $300 million and $2 billion. We then focused on companies with unusually high implied upside based on consensus analyst price targets, while avoiding stocks whose upside case depended solely on a single aggressive analyst estimate.
The final list was ranked by implied upside to consensus price target, from highest to lowest. Since exact 1,000% gains are speculative rather than measurable, the screen favored stocks with several hundred percent upside potential and broader analyst support.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. AtaiBeckley Inc. (NASDAQ:ATAI)
AtaiBeckley Inc. (NASDAQ:ATAI) is one of the small-cap stocks with potential to rise 1000 percent. The company’s investment case has become more concrete as BPL-003 moves closer to late-stage testing in treatment-resistant depression, rather than resting only on early psychedelic-drug enthusiasm. On June 8, it was reported that H.C. Wainwright reiterated a Buy rating and $25 price target on the stock after hosting AtaiBeckley management, with the firm saying BPL-003 remains the company’s core value driver as it prepares to initiate the Phase 3 ReConnection program in treatment-resistant depression.
That is important because AtaiBeckley is entering a more expensive but more valuation-relevant stage of development. In its May 12 business update, the company said BPL-003’s Phase 3 pivotal program remained on track to begin in Q2 2026, while VLS-01 Phase 2 topline data and BPL-003 Phase 2a Part 4 initial data were both expected in Q4 2026. The company also reported $209.9 million in cash, cash equivalents, and short-term securities as of March 31, 2026, and said its cash position was expected to fund operations into 2029, through anticipated BPL-003 Phase 3 topline readouts.
AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biotechnology company developing rapid-acting mental health treatments, including BPL-003 for treatment-resistant depression, VLS-01 for treatment-resistant depression, and EMP-01 for social anxiety disorder.
9. Neumora Therapeutics, Inc. (NASDAQ:NMRA)
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main near-term catalyst is navacaprant, an experimental depression treatment being tested in patients with major depressive disorder. On May 7, Neumora said two late-stage studies, KOASTAL-2 and KOASTAL-3, were fully enrolled in the first quarter of 2026, with more than 400 patients in each trial. The company expects to report combined top-line results from the two studies in the second quarter of 2026, making the update a major test of the stock’s bull case.
Neumora is also trying to build a broader brain-disease pipeline beyond navacaprant. The company said NMRA-511 remains on track to report data in the second half of 2026 from a study in agitation linked to Alzheimer’s disease, with a Phase 2 trial expected to begin in the first quarter of 2027. Another drug candidate, NMRA-898, is being tested in healthy volunteers and patients with stable schizophrenia, with Phase 1 data also expected in the second half of 2026. Neumora ended the first quarter with $147.1 million in cash and cash equivalents, which it expects to fund operations into the third quarter of 2027.
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a clinical-stage biopharmaceutical company developing treatments for brain diseases, including depression, Alzheimer’s-related agitation, and schizophrenia.
Hedge Fund Resource Center